Kim J - Search Results

1

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

Zinner RG, Kim J, Herbst RS. Zinner RG, et al. Among authors: kim j. Lung Cancer. 2002 Jul;37(1):17-27. doi: 10.1016/s0169-5002(02)00035-1. Lung Cancer. 2002. PMID: 12057863 Review.

2

Fingerprinting the circulating repertoire of antibodies from cancer patients.

Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Mintz PJ, et al. Among authors: kim j. Nat Biotechnol. 2003 Jan;21(1):57-63. doi: 10.1038/nbt774. Epub 2002 Dec 23. Nat Biotechnol. 2003. PMID: 12496764

3

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Logothetis CJ, et al. Among authors: kim j. Cancer Discov. 2013 Aug;3(8):849-61. doi: 10.1158/2159-8290.CD-12-0460. Epub 2013 Jun 28. Cancer Discov. 2013. PMID: 23811619 Free PMC article. Review.

4

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Huang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC. Huang L, et al. Among authors: kim j. Bioinformatics. 2019 Oct 1;35(19):3709-3717. doi: 10.1093/bioinformatics/btz109. Bioinformatics. 2019. PMID: 30768150 Free PMC article.

5

Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.

Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Kim J, et al. Cancer Res. 2003 Jan 15;63(2):386-93. Cancer Res. 2003. PMID: 12543792

6

Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.

Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Kim J, et al. Urol Oncol. 2003 Jan-Feb;21(1):21-6. doi: 10.1016/s1078-1439(02)00207-7. Urol Oncol. 2003. PMID: 12684123 Clinical Trial.

7

Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).

Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Tu SM, et al. Among authors: kim j. Urol Oncol. 2003 Sep-Oct;21(5):342-8. doi: 10.1016/s1078-1439(02)00300-9. Urol Oncol. 2003. PMID: 14670540

8

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Kim J, et al. Cancer Res. 2005 Jul 15;65(14):6189-98. doi: 10.1158/0008-5472.CAN-04-4439. Cancer Res. 2005. PMID: 16024620

9

Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.

Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Lin SH, et al. Among authors: kim j. Clin Cancer Res. 2008 Jun 15;14(12):3729-36. doi: 10.1158/1078-0432.CCR-08-0472. Clin Cancer Res. 2008. PMID: 18559590 Free PMC article.

10

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Tsavachidou D, et al. Among authors: kim j. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20. doi: 10.1093/jnci/djn512. Epub 2009 Feb 24. J Natl Cancer Inst. 2009. PMID: 19244175 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135,446 results

Search Page

Filters